Gene and Cell Therapy: Shaping the Future of Medicine

The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.

The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.

The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.

An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.